848 related articles for article (PubMed ID: 8810912)
1. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
[TBL] [Abstract][Full Text] [Related]
2. Genotype/phenotype correlations in Wilms' tumor.
Huff V
Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
[TBL] [Abstract][Full Text] [Related]
3. WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion.
Bardeesy N; Zabel B; Schmitt K; Pelletier J
Genomics; 1994 Jun; 21(3):663-4. PubMed ID: 7959750
[No Abstract] [Full Text] [Related]
4. Comparison of the DNA binding characteristics of the related zinc finger proteins WT1 and EGR1.
Hamilton TB; Borel F; Romaniuk PJ
Biochemistry; 1998 Feb; 37(7):2051-8. PubMed ID: 9485332
[TBL] [Abstract][Full Text] [Related]
5. Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation.
Machin GA
Birth Defects Orig Artic Ser; 1996; 30(1):269-86. PubMed ID: 9125334
[No Abstract] [Full Text] [Related]
6. Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins.
Holmes G; Boterashvili S; English M; Wainwright B; Licht J; Little M
Biochem Biophys Res Commun; 1997 Apr; 233(3):723-8. PubMed ID: 9168922
[TBL] [Abstract][Full Text] [Related]
7. Wilms' tumor 1 splice variants have opposite effects on the tumorigenicity of adenovirus-transformed baby-rat kidney cells.
Menke AL; Riteco N; van Ham RC; de Bruyne C; Rauscher FJ; van der Eb AJ; Jochemsen AG
Oncogene; 1996 Feb; 12(3):537-46. PubMed ID: 8637710
[TBL] [Abstract][Full Text] [Related]
8. Inherited WT1 mutation in Denys-Drash syndrome.
Coppes MJ; Liefers GJ; Higuchi M; Zinn AB; Balfe JW; Williams BR
Cancer Res; 1992 Nov; 52(21):6125-8. PubMed ID: 1327525
[TBL] [Abstract][Full Text] [Related]
9. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity.
Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG
Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497
[TBL] [Abstract][Full Text] [Related]
10. Exon 9 mutations in the WT1 gene, without influencing KTS splice isoforms, are also responsible for Frasier syndrome.
Kohsaka T; Tagawa M; Takekoshi Y; Yanagisawa H; Tadokoro K; Yamada M
Hum Mutat; 1999; 14(6):466-70. PubMed ID: 10571943
[TBL] [Abstract][Full Text] [Related]
11. The role of Wilms' tumor genes.
Hirose M
J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
[TBL] [Abstract][Full Text] [Related]
12. Wnt-4 regulation by the Wilms' tumour suppressor gene, WT1.
Sim EU; Smith A; Szilagi E; Rae F; Ioannou P; Lindsay MH; Little MH
Oncogene; 2002 May; 21(19):2948-60. PubMed ID: 12082525
[TBL] [Abstract][Full Text] [Related]
13. Donor splice-site mutations in WT1 are responsible for Frasier syndrome.
Barbaux S; Niaudet P; Gubler MC; Grünfeld JP; Jaubert F; Kuttenn F; Fékété CN; Souleyreau-Therville N; Thibaud E; Fellous M; McElreavey K
Nat Genet; 1997 Dec; 17(4):467-70. PubMed ID: 9398852
[TBL] [Abstract][Full Text] [Related]
14. Characterization of RNA aptamer binding by the Wilms' tumor suppressor protein WT1.
Zhai G; Iskandar M; Barilla K; Romaniuk PJ
Biochemistry; 2001 Feb; 40(7):2032-40. PubMed ID: 11329270
[TBL] [Abstract][Full Text] [Related]
15. High affinity binding sites for the Wilms' tumour suppressor protein WT1.
Hamilton TB; Barilla KC; Romaniuk PJ
Nucleic Acids Res; 1995 Jan; 23(2):277-84. PubMed ID: 7862533
[TBL] [Abstract][Full Text] [Related]
16. WT1, the Wilms' tumor suppressor gene product, represses transcription through an interactive nuclear protein.
Wang ZY; Qiu QQ; Gurrieri M; Huang J; Deuel TF
Oncogene; 1995 Mar; 10(6):1243-7. PubMed ID: 7700651
[TBL] [Abstract][Full Text] [Related]
17. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Müllerian-inhibiting substance, and the androgen receptor.
Shimamura R; Fraizer GC; Trapman J; Lau YfC ; Saunders GF
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2571-80. PubMed ID: 9815658
[TBL] [Abstract][Full Text] [Related]
18. A review of the phenotypic variation due to the Denys-Drash syndrome-associated germline WT1 mutation R362X.
Heathcott RW; Morison IM; Gubler MC; Corbett R; Reeve AE
Hum Mutat; 2002 Apr; 19(4):462. PubMed ID: 11933209
[TBL] [Abstract][Full Text] [Related]
19. Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.
Pelletier J; Bruening W; Kashtan CE; Mauer SM; Manivel JC; Striegel JE; Houghton DC; Junien C; Habib R; Fouser L
Cell; 1991 Oct; 67(2):437-47. PubMed ID: 1655284
[TBL] [Abstract][Full Text] [Related]
20. Bilateral Wilms tumor in a boy with severe hypospadias and cryptochidism due to a heterozygous mutation in the WT1 gene.
Köhler B; Schumacher V; Schulte-Overberg U; Biewald W; Lennert T; l'Allemand D; Royer-Pokora B; Grüters A
Pediatr Res; 1999 Feb; 45(2):187-90. PubMed ID: 10022588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
